Business Context and Reporting Period
Company: Protalix Biotherapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2007
Business Stage: Clinical-stage biopharmaceutical company (Development Stage Enterprise).
Operations: The Company, through its wholly-owned subsidiary Protalix Ltd. in Israel, focuses on developing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. The lead product candidate is prGCD for the treatment of Gaucher disease, which entered a pivotal Phase III clinical trial in the third quarter of 2007.
Key Financial Metrics
| Metric (in thousands, except per share) | Nine Months Ended Sep 30, 2007 | Nine Months Ended Sep 30, 2006 | Three Months Ended Sep 30, 2007 | Three Months Ended Sep 30, 2006 |
|---|---|---|---|---|
| Revenues | $830 | $0 | $0 | $0 |
| Net Loss | $(17,350) | $(5,926) | $(4,746) | $(2,499) |
| Net Loss Per Share (Basic & Diluted) | $(0.27) | $(0.28) | $(0.07) | $(0.10) |
| Research & Development Expenses | $9,537 | $4,759 | $3,830 | $2,148 |
| General & Administrative Expenses | $10,476 | $2,787 | $1,986 | $1,077 |
| Cash and Cash Equivalents (Sep 30, 2007) | $20,440 | |||
| Accumulated Deficit (Sep 30, 2007) | $(37,862) | |||
| Net Cash Used in Operating Activities (9mo) | $(6,589) | $(3,302) | N/A | |
| Net Cash Provided by Financing Activities (9mo) | $12,788 | $14,899 | N/A |
Material Changes vs. Prior Period
- Expense Growth: Research and Development (R&D) expenses increased 100% year-over-year for the nine-month period, driven by a $2.9 million increase in salaries and a $1.5 million increase in share-based compensation. General and Administrative (G&A) expenses surged 275%, primarily due to a $6.4 million increase in share-based compensation related to consultant options and higher legal/accounting fees.
- Financial Income: Net financial income increased significantly to $1.2 million for the nine months ended September 30, 2007, compared to $73,000 in the prior year, largely due to interest income on cash proceeds from share sales and warrant exercises.
- Revenue: The Company recorded $830,000 in revenue for the nine-month period, compared to zero in the prior year, though this remains immaterial relative to operating costs.
- Cash Position: Cash and cash equivalents increased from $15.4 million at year-end 2006 to $20.4 million at September 30, 2007, despite significant operating cash burn, due to financing activities including warrant exercises.
Guidance, Outlook, and Risks
- Subsequent Event (Financing): On October 25, 2007, the Company completed an underwritten public offering of 10 million shares at $5.00 per share, raising approximately $46.0 million in net proceeds. An option to purchase an additional 1.5 million shares remains available.
- Liquidity Outlook: Management believes current resources, including the October 2007 offering proceeds, are sufficient to fund planned research, operating, and capital needs for at least the next 24 months.
- Future Funding: The Company expects to continue incurring substantial losses and will require additional financing through equity, debt, or collaborations to complete commercialization.
- Key Risks:
- Regulatory approval delays or rejection by the FDA and other authorities.
- Failure to enroll patients in clinical trials or achieve positive trial results.
- Dependence on the success of the prGCD Phase III trial.
- Need for significant capital expenditures for a new FDA-compliant manufacturing facility.
- Currency fluctuation risks (approx. 50% of costs incurred in New Israeli Shekels).
Investor Verification Checklist
- Cash Runway: Verify the impact of the October 2007 $46 million offering on the 24-month liquidity runway stated by management.
- Share-Based Compensation: Review the magnitude of non-cash share-based compensation ($10.2 million in the nine months ended Sep 30, 2007) and its effect on reported net loss versus cash burn.
- Clinical Trial Progress: Confirm the status of patient enrollment and data readouts for the prGCD Phase III trial for Gaucher disease.
- Manufacturing Plans: Assess the timeline and capital requirements for the proposed new manufacturing facility to meet FDA standards.
- Revenue Sustainability: Evaluate the source and sustainability of the $830,000 revenue recorded, as the Company has no approved commercial products.